Notice of Half Year Results

RNS Number : 9391O

MaxCyte, Inc.

25 August 2017

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Half Year Results

Maryland, USA - 25 August 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, will announce its interim results for the six months ended 30 June 2017 on Tuesday 19 September 2017.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11:00 BST on the day of the results at the offices of Panmure Gordon, 1 New Change, London EC4M 9AF.

For further information, please contact:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	[phone]
Nominated Adviser and Broker Panmure Gordon
Freddy Crossley (Corporate Finance) Duncan Monteith Ryan McCarthy Tom Salvesen (Corporate Broking)	[phone]
Financial PR Adviser Consilium Strategic Communications
Mary-Jane Elliott Chris Welsh Lindsey Neville	[phone] [e-mail]

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines.

MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.  

For more information, visit http://www.maxcyte.com/ 

 

END

 

 

NORPIMITMBTTBIR